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Introduction
Direct oral anticoagulants (DOACs) have been licensed for use at fixed dosages without adjustment by laboratory testing [1] . However, it is increasingly being appreciated that laboratory testing is required in special circumstances [2] [3] [4] [5] . Dedicated tests such as the dilute thrombin time (dTT), ecarin clotting (or chromogenic) and anti-activated factor X assays have been developed and marketed to measure the anticoagulant effect of dabigatran or rivaroxaban and apixaban. Reports on the performance of some of these tests and the influence that DOAC may have on coagulation tests have been published [6] [7] [8] , but data stemming from the interlaboratory variability of DOAC concentration assessed in external quality-control schemes are not available. The Italian Federation of Thrombosis Centers has a longstanding tradition of proficiency testing for the International Normalized Ratio (INR) [9] . Over the last year, we expanded the scheme by organizing and carrying out proficiency surveys to assess the interlaboratory variability in measurement of DOAC concentrations.
Design
Surveys were organized and carried out in 2016-2017 on two occasions. In the first, devoted to dabigatran, three freeze-dried plasmas (Werfen, Orangeburg, NY, USA) were included: one was free from dabigatran, and two contained purified drug at low and intermediate concentrations. The second, devoted to dabigatran, rivaroxaban, and apixaban, included one plasma free from DOAC and others supplemented with either dabigatran, rivaroxaban, or apixaban (Werfen). The DOAC composition/concentration in the proficiency plasmas was unknown to the participants, who were asked to measure prothrombin time (PT), activated partial thromboplastin time (APTT), and thrombin time (TT), and to measure the concentration of the three drugs with dedicated tests. Participants were asked to use local methods according to manufacturer specifications to perform the tests and for calibration. The results were sent to the organizing center (Milano) by use of a web-based system. They were expressed as clotting time ratio (patient/normal) for PT, APTT and TT, and concentrations (ng mL À1 ) for each DOAC. The analysis included the calculation of the overall mean (consensus) value and coefficient of variation (CV) within each method after the exclusion of outliers [10] , regardless of the reagent used. The percentage of participants who reported concentrations for each DOAC of < 30 ng mL -1 for the plasmas that were free from DOAC was also calculated.
Results and discussion

Survey I
PT. Mean PT ratios were 1.04 for the plasma free from dabigatran, 1.05 for the plasma with a low level (i.e. 42 ng mL
À1
), and 1.23 for the plasma with an intermediate level (i.e. 182 ng mL À1 ). The interlaboratory CV was < 4.4% (Table 1 ; Fig. 1 ).
APTT. Mean APTT ratios were 0.99 for the plasma free from dabigatran, 1.30 for the plasma with a low level (i.e. 42 ng mL À1 ), and 1.87 for the plasma with an intermediate level (i.e. 182 ng mL À1 ). The interlaboratory CV was < 9.2%.
TT. Mean TT ratios were 0.99 for the plasma free from dabigatran, 7.6 for the plasma with a low level (i.e. 42 ng mL
), and 15.4 for the plasma with an intermediate level (i.e. 182 ng mL À1 ). The interlaboratory CV was 12-65%.
Dabigatran concentration. The methods used for dabigatran measurement included dTT from different manufacturers (see figure legends for more details, where groups of participants using the same method are reported). The mean dabigatran concentration estimated by participants for the plasma free from dabigatran was 0.20 ng mL À1 ,
with a large range of values (from 0 ng mL À1 to 43 ng mL
). Ninety-five per cent of the participants reported concentrations of < 30 ng mL À1 ; 18% reported results corresponding to 0 ng mL À1 ; and 18% reported that concentrations were smaller than the quantification limits of their methods. The mean value calculated for the participants (n = 5) using the BC thrombin reagent from Siemens when testing the plasma free from dabigatran was barely distinguishable from the mean value calculated for the same group of participants for the plasma containing a relatively low concentration of dabigatran (Fig. 1) . Mean dabigatran concentrations for the plasmas with low and Table 1 Parameters of coagulation and interlaboratory variation as observed by participants when measuring common freeze-dried plasmas without (plasma C) or with (plasmas E and D) dabigatran (Survey I)
PT ratio APTT ratio TT ratio 
APTT, activated partial thromboplastin time; CV, coefficient of variation; PT, prothrombin time; TT, thrombin time. *Mean and CV values were calculated after exclusion of outliers [10] . †Percentage of participants who reported a dabigatran concentration of < 30 ng mLÀ1 for plasma C (free from the drug).
intermediate levels were 42 ng mL À1 and 182 ng mL À1 , respectively. The interlaboratory CV was < 13.9%. APTT-Mean APTT ratios were 0.99 for the plasma free from dabigatran and 1.85 for the plasma with an intermediate level (i.e.177 ng mL
). The interlaboratory CVs were 6.2% for the plasma free from dabigatran and 5.8% for the plasma with an intermediate concentration (i.e. 177 ng mL À1 ).
TT-Mean TT ratios were 1.03 for the plasma free from dabigatran and undefined for the plasma with an intermediate level (i.e. 177 ng mL
). In fact, most participants reported that the TT for this plasma was 'unclottable'. The interlaboratory CVs were 11.9% for the plasma free from dabigatran and undefined for the plasma with an intermediate level (i.e. 177 ng mL À1 ).
Dabigatran concentrations-The mean dabigatran concentration estimated by participants for the plasma free from dabigatran was 5.3 ng mL À1 , with a large range of values (from 0 ng mL À1 to 52 ng mL À1 ). The interlaboratory CVs were 4.0% for the plasma free from rivaroxaban and 6.2% for the plasma with a relatively low level (i.e. 81 ng mL
).
APTT-Mean APTT ratios were 0.99 for the plasma free from rivaroxaban and 1.16 for the plasma with a relatively low level (i.e. 81 ng mL À1 ). The interlaboratory CVs were 6.2% for the plasma free from rivaroxaban and 8.3% for the plasma with a relatively low level (i.e. 81 ng mL
TT-Mean TT ratios were 1.03 for the plasma free from rivaroxaban and 1.03 for the plasma containing the drug.
Rivaroxaban concentration-The mean rivaroxaban concentration estimated by participants for the plasma free from rivaroxaban was 4.2 ng mL
, with a large range of values (from 0 ng mL À1 to 58 ng mL
). Ninety-six per cent of the participants reported concentrations of < 30 ng mL À1 or lower than the quantification limits of their methods. The mean rivaroxaban concentration for the plasma with a relatively low drug level was 81 ng mL
, and the interlaboratory CV was 8.4%.
Apixaban PT-Mean PT ratios were 1.00 for the plasma free from apixaban and 1.07 for the plasma with a relatively low level (i.e. 66 ng mL À1 ). The interlaboratory CVs were 4.0% for the plasma free from apixaban and 4.6% for the plasma with a relatively low level (i.e. 66 ng mL
APTT-Mean APTT ratios were 0.99 for the plasma free from apixaban and 1.08 for the plasma with a relatively low level (i.e. 66 ng mL
). The interlaboratory CVs were 6.2% for the plasma free from apixaban and 7.4% for the plasma with a relatively low level (i.e. 66 ng mL
TT-Mean TT ratios were 1.03 for the plasma free from apixaban and 1.03 for the plasma containing the drug.
Apixaban concentration-The mean apixaban concentration estimated by participants for the plasma free from apixaban was 5.4 ng mL À1 , with a large range of values (from 0 ng mL À1 to 50 ng mL
). Ninety-nine percent of the participants reported concentrations of < 30 ng mL À1 or lower than the quantification limits of their methods. The mean apixaban concentration for the plasma with a relatively low level was 66 ng mL
, and the interlaboratory CV was 10.3%.
Despite calls for the contrary [11] , DOAC measurement in clinical laboratories is not widely available. The reasons for this state of affairs are varied.
First, there is confusion regarding two distinct concepts: 'monitoring', which implies dose adjustment of anticoagulants by laboratory testing (typically, vitamin K antagonists and heparins); and 'measuring', which implies measurement of the plasma drug concentration for reasons other than dose adjustment [12] . DOACs have been licensed for prescription at fixed dosages, and do not require 'monitoring', but this does not necessarily imply that they do not require 'measuring', although they do in special circumstances. It is increasingly accepted that special situations in which 'measuring' is required are the following [2] [3] [4] [5] [11] [12] [13] [14] [15] [16] [17] : (i) impaired renal function; (ii) to make decisions regarding thrombolytic therapy in stroke patients; (iii) when there are adverse events (hemorrhage/ thrombosis); (iv) to make decisions regarding immediate reversal of anticoagulation with antidotes; and (v) in the event of surgery/invasive procedures. For all of the above situations, the arguments for 'measuring' have been discussed [2] [3] [4] [5] [11] [12] [13] [14] [15] [16] [17] . There are also situations in which 'measuring' would be useful, albeit not strictly required: (i) patients with extreme body weight; (ii) before initiation (and a few weeks later) of additional drugs for which interference with DOACs is unknown; and (iii) when chronic anticoagulation is achieved [2, 12] .
Second, although realizing the difference between 'monitoring' and 'measuring', many clinicians are reluctant to ask for DOAC measurement, as they believe that the basic PT/APTT tests, with which they are more familiar, are sufficient to draw conclusions on the level of anticoagulation. Furthermore, specific tests for DOACs may be perceived as having obscure significance (difficult names that are outside the understanding of many), difficult to perform (especially in small hospitals and in emergencies), and to have between-laboratory variability.
Third, regulatory authorities have not yet issued recommendations on which test should be used and in which situations [11] . The above state of affairs has generated a vicious circle, whereby clinicians do not ask for testing and clinical laboratories do not set up the assays or make them promptly available. The experience reported in this article shows that most of the perception that surrounds specific tests for DOACs is not supported by evidence stemming from practice. The results of the external quality-control scheme show the following arguments that can be used to interrupt the vicious circle and make specific tests for DOACs available and used by clinicians for better management of anticoagulated patients. (i) PT and APTT cannot be safely used to draw conclusions on the levels of anticoagulation in patients receiving DOACs. They are variably prolonged in response to DOACs, but their responsiveness is not sufficient to enable conclusions to be drawn on the level of anticoagulation; this holds true [16] especially for PT and APTT when they are used to test the apixaban anticoagulant effect [18, 19] . (ii) TT (which is very simple to perform and can be set up in any ordinary coagulometer) is normal in patients taking rivaroxaban or apixaban; it is heavily prolonged in patients taking dabigatran, but is normal when the plasma is free from dabigatran. The conclusion is that a normal TT can rule out dabigatran. (iii) Specific tests are responsive to the effect of the DOAC. (iv) The interlaboratory variability of results for the plasmas at low-intermediate drug concentrations is acceptable, being of the same magnitude as that observed within the same exercise for the INR (average CV: 9.1% versus 11.4%), in spite of the fact that no international standards for DOACs are available. The interlaboratory variability when plasmas are free from DOACs is large, and this is probably attributable to the poor limits of quantifcation of some of the tests. This should be regarded as a limitation, and could be overcome by appropriate modifications of the testing protocol (reading time, sample volume, sample dilution, calibrators dilution, etc.), which are available for some methods. Alternatively, results that are very close to or smaller than the lower limit of quantification should be reported only qualitatively as being lower than the lower limit of the numerical (quantification) value. From a practical standpoint, this reporting is meaningful, as clinicians need to know whether the drug concentration is very low.
There are limitations of the study. First, the number of participants is relatively small. They are, however, general, unselected laboratories representing the average to which thrombosis centers across the country refer for control of anticoagulation. The control plasmas used in the surveys should have been from patients receiving DOACs. However, for the purpose of this survey (i.e. assessing the interlaboratory variation), pooled normal plasmas spiked with graded DOAC concentrations are appropriate.
In conclusion, the results of the external quality-control scheme for DOACs involving unselected clinical laboratories show that measurement of the DOAC plasma concentration in a real-life situation is reliable, and that the interlaboratory variability is low and compares favorably with that of the INR. Regulatory authorities should urgently issue recommendations on their use, and clinical laboratories should set up specific methods for each drug and make them available even in emergency departments. 
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